|
Board of Directors
Robert B. Cameron, M.D.
UCLA Medical School
Nicholas J. Vogelzang, M.D.
University of Chicago
Brian Loggie, M.D.
University of Texas SW Medical
Robert Ginsberg, M.D.
Memorial Sloan Kettering
Michael Harbut, M.D.
Wayne State University
Roger G. Worthington, Esq.
Dallas, Texas
Robert I. Komitor, Esq.
New York, New York
Susan Vento
St. Paul, Minnesota
In Memorium
Congressman Bruce F. Vento
Bill Powell
Science Advisory Board
Harvey Pass, M.D., Chairman
Karmanos Cancer Institute
Victor Roggli, M.D.
Duke University
Robert N. Taub, M.D.
Columbia University
Lary A. Robinson, M.D.
H. Lee Moffit Cancer Center
Steve Hahn, M.D.
University of Pennsylvania
Joseph R. Testa, Ph.D.
Fox Chase Cancer Center
Claire Verschraegen, M.D.
M.D. Anderson/Univ. of Texas
Eric Vallieres, M.D.
University of Washington
Dan Miller, M.D.
Mayo Clinic
Raphael Bueno, M.S.
Harvard/Brigham and Women's
Hedy Lee Kindler, M.D.
University of Chicago
W.Roy Smythe, M.D.
M.D. Anderson/Univ. of Texas
Executive Director
Christopher E. Hahn
Santa Barbara, CA
MARF, inc.
1609 Garden Street
Santa Barbara, CA 93101
tel (805) 560-8942
fax (805) 560-8962
http://www.marf.org
c-hahn@marf.org
|
Our Mission is to eradicate mesothelioma as a life-ending
disease.
July 16, 2001
Nick Abaza, Esq. Hissey, Keintz & Harron
P.L.L.C 16800 Imperial Valley Drive, Ste
130 Houston, TX 77060
Dear Mr. Abaza:
After he was diagnosed with mesothelioma last year,
Congressman Bruce Vento made a public plea
for all groups involved with asbestos to unite in the
Mesothelioma Applied Research Foundation's mission of
eradicating the disease. To asbestos lawyers he said,
"I ask you to expand your role as advocates. You
have done good work in advocacy for your clients, but every
mesothelioma patient's first priority is life. He or she
wants to live. You have the resources, wisdom and compassion.
Please help commensurate with your wealth and
knowledge."
As members of MARF's Board of Directors and Science
Advisory Board, we write to ask you to answer Congressman
Vento's call and join us now in support of MARF's
life-saving work. We have vision and energy, and we are
becoming a powerful force in raising awareness, raising
research funding, and finding a cure for the disease.
Through its first two research grants of $100,000 each, MARF
is already funding two excellent projects. One is at the
University of Chicago, studying the anti-angiogenesis drug,
SU5416, which specifically targets a growth factor present at
higher levels in mesothelioma than any other solid tumor. The
other, at Fox Chase Cancer Center, is narrowing in on a tumor
suppressor gene frequently deleted in mesothelioma, and could
yield powerful gene therapies.
For our second round of grants, which will be awarded July
31, we have ten applications from major cancer research
centers for interesting, novel projects. This demonstrates
that MARF is accomplishing its goal of drawing top-flight
researchers to mesothelioma. We will fund two of these
projects this round, at $100,000 each. As our own funding
grows, we will be able to speed the search for a cure by
making more and larger research grants.
We are also hard at work on two exciting new ideas. First, we
are forming a Family Advocacy Board. MARF will provide the
leadership and financial and administrative support to create
a platform for the people hurt the most by this disease - the
mesothelioma patients and family members themselves - to
organize, be empowered and make a difference. The goal is
literally that some day the patients and their families will
take the reigns of MARF.
We are also working on a collaborative project among all the
MARF researchers. As this project develops, it will be
expandable to others, and will also qualify the participating
researchers as a "group," eligible for NIH funding
for additional mesothelioma research projects. Again, this
furthers our goal of drawing additional research dollars to
mesothelioma.
Finally, we are privileged to announce that Susan Vento has
joined our Board of Directors. Mrs. Vento will help us draw
political attention to the disease and the need for research
funding. Also, her talent and years of experience as a union
organizer (school teachers) will be of great help in
organizing and motivating the Family Advocacy Board.
All of these developments show how serious MARF is in its
mission to eradicate mesothelioma, and the tremendous
momentum we have generated. We are on the verge of the
critical mass which will establish us as a long-term,
powerful organization. Your firm can help MARF accomplish its
mission - the eradication of mesothelioma as a life-ending
disease - by joining MARF now as a sponsoring Member. Your
colleagues from nine major firms have already become Members
(they are listed on the MARF website). We ask you to answer
Congressman Vento's call, and join them in MARF's
life-saving mission.
We appreciate your time and generosity, and would be happy to
speak to you further about MARF. If you would like additional
information, please contact any one of us or MARF's
Executive Director, Chris Hahn (805.560.8942,
c-hahn@marf.org), or visit the MARF website
(http://www.marf.org).
Sincerely,
|
|
|
|
|
Raphael Bueno, M.D.
|
Robert B. Cameron, M.D.
|
Robert Ginsberg, M.D.
|
|
|
|
|
|
Steve Hahn, M.D.
|
Michael Harbut, M.D.
|
Hedy Lee Kindler, M.D.
|
|
|
|
|
|
Brian Loggie, M.D.
|
Dan Miller, M.D.
|
Harvey Pass, M.D.
|
|
|
|
|
|
Lary A. Robinson, M.D.
|
Victor Roggli, M.D.
|
W. Roy Smythe, M.D.
|
|
|
|
|
|
Joseph R. Testa
|
Eric Vallieres, M.D.
|
Susan Vento
|
|
|
|
|
|
Claire Verschraegen, M.D.
|
Nicholas J. Vogelzang, M.D.
|
|
|